アジレント・テクノロジー株式会社 Company Profile

This is a chance to introduce the best-selling HPLC "Infinity III LC" at a special price, available only now. The campaign price starts at 3,990,000 yen (excluding tax), including a PC and installation adjustment costs, allowing you to start operations immediately. In addition to its space-saving design with a width of just 39.6 cm, it is equipped with InfinityLab Assist, which realizes next-generation operability. Automation of analysis preparation and shutdown significantly improves productivity, increases operational rates, and reduces maintenance frequency. With globally proven robustness and reliability, it can be operated safely for the long term. Online demos are also available, introducing the actual machine in about 30 minutes. Of course, it's also fine to request materials only!

We will be holding a webinar to introduce the latest information on "LC," "LC/MS," and "PFAS analysis," based on the content that received positive feedback at the JASIS 2025 exhibitor seminar held in September 2025. We aim to provide useful information for those interested in improving the efficiency of LC analysis and regulatory compliance. We encourage you to take this opportunity to participate. We sincerely look forward to your participation.

In this webinar, we will welcome Dr. Kazuhisa Uchida from the Bioeducation and Research Promotion Organization (BECRET) to give a lecture on the challenges and latest trends in human resource development in the biopharmaceutical field. Additionally, Agilent will introduce analytical technologies that support the manufacturing processes of antibody drugs, as well as the latest solutions and automation technologies that are useful for research and development, providing information that contributes to solving on-site challenges. Lecture 1: "Latest Trends in Human Resource Development and Education in the Biopharmaceutical Field" Bioeducation and Research Promotion Organization (BECRET) Executive Director, Dr. Kazuhisa Uchida The diversification of antibody drugs, the expansion of modalities in the fields of viral vectors, mRNA vaccines, and cell therapies, as well as an increase in CMC (Chemistry, Manufacturing, and Controls) operations, have led to a rise in biopharmaceutical manufacturing sites domestically. Consequently, there is a shortage of personnel related to CMC and GMP (Good Manufacturing Practice) manufacturing, which has become a challenge. One approach to solving this issue is the expectation for automation of manufacturing and analytical equipment. Lecture 2: "Agilent's Latest Technologies and Solutions Supporting Biopharmaceutical Manufacturing"